Search

Your search keyword '"Kim, Sung-Rae"' showing total 297 results
Start Over Author "Kim, Sung-Rae"
297 results on '"Kim, Sung-Rae"'

51. Efficacy and Safety of Voglibose Plus Metformin in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial

Author

Oh, Tae Jung, primary, Yu, Jae Myung, additional, Min, Kyung Wan, additional, Son, Hyun Shik, additional, Lee, Moon Kyu, additional, Yoon, Kun Ho, additional, Song, Young Duk, additional, Park, Joong Yeol, additional, Jeong, In Kyung, additional, Cha, Bong Soo, additional, Kim, Yong Seong, additional, Baik, Sei Hyun, additional, Kim, In Joo, additional, Kim, Doo Man, additional, Kim, Sung Rae, additional, Lee, Kwan Woo, additional, Park, Jeong Hyung, additional, Lee, In Kyu, additional, Park, Tae Sun, additional, Choi, Sung Hee, additional, and Park, Sung Woo, additional

Published
2019
Full Text
View/download PDF

53. Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double-blind, non-inferiority trial

Author

Kim, Yonghyun, primary, Kang, Eun Seok, additional, Jang, Hak Chul, additional, Kim, Dong Jun, additional, Oh, Taekeun, additional, Kim, Eun Sook, additional, Kim, Nan-Hee, additional, Choi, Kyung Mook, additional, Kim, Sung-Rae, additional, You, JiYoung, additional, Kim, Se-Jin, additional, and Lee, Moon-Kyu, additional

Published
2018
Full Text
View/download PDF

64. Solid formulation of a supersaturable self-microemulsifying drug delivery system for valsartan with improved dissolution and bioavailability

Author

Yeom, Dong Woo, primary, Chae, Bo Ram, additional, Kim, Jin Han, additional, Chae, Jun Soo, additional, Shin, Dong Jun, additional, Kim, Chang Hyun, additional, Kim, Sung Rae, additional, Choi, Ji Ho, additional, Song, Seh Hyon, additional, Oh, Dongho, additional, Sohn, Se Il, additional, and Choi, Young Wook, additional

Published
2017
Full Text
View/download PDF

71. Teneligliptin versus sitagliptin in Korean patients with type 2 diabetes inadequately controlled with metformin and glimepiride: A randomized, double‐blind, non‐inferiority trial.

Author

Kim, Yonghyun, Kang, Eun Seok, Jang, Hak Chul, Kim, Dong Jun, Oh, Taekeun, Kim, Eun Sook, Kim, Nan‐Hee, Choi, Kyung Mook, Kim, Sung‐Rae, You, JiYoung, Kim, Se‐Jin, and Lee, Moon‐Kyu

Subjects
CD26 antigen, SITAGLIPTIN, HYPOGLYCEMIC agents, PEOPLE with diabetes, TREATMENT of diabetes, METFORMIN, CLINICAL trials
Abstract

Aim: To assess the efficacy and safety of add‐on therapy with the dipeptidyl peptidase‐4 inhibitor teneligliptin compared with sitagliptin in patients with type 2 diabetes (T2DM) inadequately controlled with metformin and glimepiride. Materials and Methods: This was a phase 3, randomized, double‐blind, non‐inferiority study of adult Korean subjects with T2DM (n = 201), with HbA1c ranging from 7.0% to 11.0%, on stable doses of metformin plus glimepiride. Subjects were randomized in a 1:1 fashion to receive either oral teneligliptin 20 mg or sitagliptin 100 mg for 24 weeks. The primary endpoint was change from baseline in HbA1c. Results: At baseline, mean age was 60.56 ± 9.41 years, body mass index was 25.23 ± 2.85 kg/m2 and HbA1c was 8.11% ± 0.79%. At 24 weeks, both groups achieved significant reductions from baseline in HbA1c (teneligliptin, −1.03% ± 0.10% [P < 0.0001]; sitagliptin, −1.02% ± 0.10% [P < 0.0001]). The inter‐group difference was −0.01% (95% confidence interval [CI]: −0.28, 0.26; P = 0.9497); the upper limit of the 95% CI was within the preset limit for non‐inferiority (0.4%). There were no significant differences between groups in the proportion of patients achieving HbA1c targets, or changes from baseline in fasting plasma glucose, body weight or lipid levels at 24 weeks. Rates of adverse events (teneligliptin, n = 63 [61.76%]; sitagliptin, n = 61 [62.24%]; P = 0.9442) and hypoglycaemia (teneligliptin, n = 32 [31.37%]; sitagliptin, n = 28 [28.57%]; P = 0.6656) were similar. Conclusion: Teneligliptin was non‐inferior to sitagliptin in the context of triple therapy for T2DM and is an important option in this setting. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

73. Development of a chitosan based double layer-coated tablet as a platform for colon-specific drug delivery

Author

Kim,Min Soo, Yeom,Dong Woo, Kim,Sung Rae, Yoon,Ho Yub, Kim,Chang Hyun, Son,Ho Yong, Kim,Jin Han, Lee,Sangkil, Choi,Young Wook, Kim,Min Soo, Yeom,Dong Woo, Kim,Sung Rae, Yoon,Ho Yub, Kim,Chang Hyun, Son,Ho Yong, Kim,Jin Han, Lee,Sangkil, and Choi,Young Wook

Abstract

Min Soo Kim,1,* Dong Woo Yeom,1,* Sung Rae Kim,1 Ho Yub Yoon,1 Chang Hyun Kim,1 Ho Yong Son,1 Jin Han Kim,1 Sangkil Lee,2 Young Wook Choi1 1College of Pharmacy, Chung-Ang University, Seoul, 2College of Pharmacy, Keimyung University, Daegu, South Korea *These authors contributed equally to this work Abstract: A double layer-coated colon-specific drug delivery system (DL-CDDS) was developed, which consisted of chitosan (CTN) based polymeric subcoating of the core tablet containing citric acid for microclimate acidification, followed by an enteric coating. The polymeric composition ratio of Eudragit E100 and ethyl cellulose and amount of subcoating were optimized using a two-level factorial design method. Drug-release characteristics in terms of dissolution efficiency and controlled-release duration were evaluated in various dissolution media, such as simulated colonic fluid in the presence or absence of CTNase. Microflora activation and a stepwise mechanism for drug release were postulated. Consequently, the optimized DL-CDDS showed drug release in a controlled manner by inhibiting drug release in the stomach and intestine, but releasing the drug gradually in the colon (approximately 40% at 10 hours and 92% at 24 hours in CTNase-supplemented simulated colonic fluid), indicating its feasibility as a novel platform for CDD. Keywords: chitosan, colon-specific delivery, acidification, microflora, factorial design, controlled release

Published
2016

74. Increased localized delivery of piroxicam by cationic nanoparticles after intra-articular injection

Author

Kim,Sung Rae, Ho,Myoung Jin, Kim,Sang Hyun, Cho,Ha Ra, Kim,Han Sol, Choi,Yong Seok, Choi,Young Wook, Kang,Myung Joo, Kim,Sung Rae, Ho,Myoung Jin, Kim,Sang Hyun, Cho,Ha Ra, Kim,Han Sol, Choi,Yong Seok, Choi,Young Wook, and Kang,Myung Joo

Abstract

Sung Rae Kim,1 Myoung Jin Ho,2 Sang Hyun Kim,1 Ha Ra Cho,2 Han Sol Kim,2 Yong Seok Choi,2 Young Wook Choi,1 Myung Joo Kang2 1Division of Pharmaceutical Sciences, College of Pharmacy, Chung-Ang University, Seoul, 2College of Pharmacy, Dankook University, Cheonan, Chungnam, South Korea Abstract: Piroxicam (PRX), a potent nonsteroidal anti-inflammatory drug, is prescribed to relieve postoperative and/or chronic joint pain. However, its oral administration often results in serious gastrointestinal adverse effects including duodenal ulceration. Thus, a novel cationic nanoparticle (NP) was explored to minimize the systemic exposure and increase the retention time of PRX in the joint after intra-articular (IA) injection, by forming micrometer-sized electrostatic clusters with endogenous hyaluronic acid (HA) in the synovial cavity. PRX-loaded NPs consisting of poly(lactic-co-glycolic acid), Eudragit RL, and polyvinyl alcohol were constructed with the following characteristics: particle size of 220 nm, zeta potential of 11.5 mV in phosphate-buffered saline, and loading amount of 4.0% (w/w) of PRX. In optical and hyperspectral observations, the cationic NPs formed more than 50 µm-sized aggregates with HA, which was larger than the intercellular gaps between synoviocytes. In an in vivo pharmacokinetic study in rats, area under the plasma concentration–time curve (AUC0–24 h) and maximum plasma concentration (Cmax) of PRX after IA injection of the cationic NPs were <70% (P<0.05) and 60% (P<0.05), respectively, compared to those obtained from drug solution. Moreover, the drug concentration in joint tissue 24 h after dosing with the cationic NPs was 3.2-fold (P<0.05) and 1.8-fold (P<0.05) higher than that from drug solution and neutrally charged NPs, respectively. Therefore, we recommend the IA cationic NP therapy as an effective alternative to traditional oral therapy with PRX, as

Published
2016

85. Cationic PLGA/Eudragit RL nanoparticles for increasing retention time in synovial cavity after intra-articular injection in knee joint

Author

Kim,Sung Rae, Ho,Myoung Jin, Lee,Eugene, Lee,Joon Woo, Choi,Young Wook, Kang,Myung Joo, Kim,Sung Rae, Ho,Myoung Jin, Lee,Eugene, Lee,Joon Woo, Choi,Young Wook, and Kang,Myung Joo

Abstract

Sung Rae Kim,1 Myoung Jin Ho,2 Eugene Lee,3 Joon Woo Lee,3 Young Wook Choi,1 Myung Joo Kang21College of Pharmacy, Chung-Ang University, Dongjak-gu, Seoul, 2College of Pharmacy, Dankook University, Dongnam-gu, Cheonan, Chungnam, 3Department of Radiology, Seoul National University Bundang Hospital, Bundang-gu, Seongnam, Gyeonggi-do, South KoreaAbstract: Positively surface-charged poly(lactide-co-glycolide) (PLGA)/Eudragit RL nanoparticles (NPs) were designed to increase retention time and sustain release profile in joints after intra-articular injection, by forming micrometer-sized electrostatic aggregates with hyaluronic acid, an endogenous anionic polysaccharide found in high amounts in synovial fluid. The cationic NPs consisting of PLGA, Eudragit RL, and polyvinyl alcohol were fabricated by solvent evaporation technique. The NPs were 170.1 nm in size, with a zeta potential of 21.3 mV in phosphate-buffered saline. Hyperspectral imaging (CytoViva®) revealed the formation of the micrometer-sized filamentous aggregates upon admixing, due to electrostatic interaction between NPs and the polysaccharides. NPs loaded with a fluorescent probe (1,1'-dioctadecyl-3,3,3',3' tetramethylindotricarbocyanine iodide, DiR) displayed a significantly improved retention time in the knee joint, with over 50% preservation of the fluorescent signal 28 days after injection. When DiR solution was injected intra-articularly, the fluorescence levels rapidly decreased to 30% of the initial concentration within 3 days in mice. From these findings, we suggest that PLGA-based cationic NPs could be a promising tool for prolonged delivery of therapeutic agents in joints selectively.Keywords: PLGA, Eudragit RL, hyaluronic acid, cationic nanoparticles, intra-articular injection, electrostatic interaction

Published
2015

86. Development and optimization of a self-microemulsifying drug delivery system for atorvastatin calcium by using D-optimal mixture design

Author

Yeom,Dong Woo, Song,Ye Seul, Kim,Sung Rae, Lee,Sang Gon, Kang,Min Hyung, Lee,Sangkil, Choi,Young Wook, Yeom,Dong Woo, Song,Ye Seul, Kim,Sung Rae, Lee,Sang Gon, Kang,Min Hyung, Lee,Sangkil, and Choi,Young Wook

Abstract

Dong Woo Yeom,1 Ye Seul Song,1 Sung Rae Kim,1 Sang Gon Lee,1 Min Hyung Kang,1 Sangkil Lee,2 Young Wook Choi1 1College of Pharmacy, Chung-Ang University, Seoul, 2College of Pharmacy, Keimyung University, Daegu, Republic of Korea Abstract: In this study, we developed and optimized a self-microemulsifying drug delivery system (SMEDDS) formulation for improving the dissolution and oral absorption of atorvastatin calcium (ATV), a poorly water-soluble drug. Solubility and emulsification tests were performed to select a suitable combination of oil, surfactant, and cosurfactant. A d-optimal mixture design was used to optimize the concentration of components used in the SMEDDS formulation for achieving excellent physicochemical characteristics, such as small droplet size and high dissolution. The optimized ATV-loaded SMEDDS formulation containing 7.16% Capmul MCM (oil), 48.25% Tween 20 (surfactant), and 44.59% Tetraglycol (cosurfactant) significantly enhanced the dissolution rate of ATV in different types of medium, including simulated intestinal fluid, simulated gastric fluid, and distilled water, compared with ATV suspension. Good agreement was observed between predicted and experimental values for mean droplet size and percentage of the drug released in 15 minutes. Further, pharmacokinetic studies in rats showed that the optimized SMEDDS formulation considerably enhanced the oral absorption of ATV, with 3.4-fold and 4.3-fold increases in the area under the concentration-time curve and time taken to reach peak plasma concentration, respectively, when compared with the ATV suspension. Thus, we successfully developed an optimized ATV-loaded SMEDDS formulation by using the d-optimal mixture design, that could potentially be used for improving the oral absorption of poorly water-soluble drugs. Keywords: atorvastatin, SMEDDS, d-optimal mixture design, optimization, dissolution, bioavailability&nbsp

Published
2015

96. Two Cases of Allergy to Insulin in Gestational Diabetes

Author

Kim, Gi Jun, primary, Kim, Shin Bum, additional, Jo, Seong Il, additional, Shin, Jin Kyeong, additional, Kwon, Hee Sun, additional, Jeong, Heekyung, additional, Son, Jang Won, additional, Lee, Seong Su, additional, Kim, Sung Rae, additional, Kim, Byung Kee, additional, and Yoo, Soon Jib, additional

Published
2015
Full Text
View/download PDF

99. PROPIT: A PROspective comparative clinical study evaluating the efficacy and safety of PITavastatin in patients with metabolic syndrome

Author

Choi, Sung Hee, primary, Lim, Soo, additional, Hong, Eun Shil, additional, Seo, Ji A, additional, Park, Cheol-Young, additional, Noh, Jung Hyun, additional, Mok, Ji Oh, additional, Lee, Ki Young, additional, Park, Jong Sook, additional, Kim, Dae Jung, additional, Lee, Chang Beom, additional, Kim, Sung Rae, additional, and Jang, Hak Chul, additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results